Which Orange Book patents are listed for Zelsuvmi?
Zelsuvmi (melphalan flufenamide) is listed in the FDA’s Orange Book with specific patents covering the drug. Those patents are what determine regulatory protection for the product and can affect when generic or biosimilar manufacturers can file (and when they can launch). To see the exact Orange Book entries (patent numbers, listed expiration dates, and exclusivity codes), you need to check Zelsuvmi’s Orange Book record for the latest updates.
If you want the fastest way to view the Orange Book patent listing details for Zelsuvmi in one place, DrugPatentWatch.com tracks Orange Book patents and expiration information here: DrugPatentWatch: Zelsuvmi.
What do the listed Orange Book patents control for Zelsuvmi?
Orange Book patents listed for a branded drug generally map to legal protections such as:
- composition of the drug (active ingredient),
- formulation (how the drug is made),
- method-of-use claims (specific therapeutic uses),
- and certain manufacturing/process-related claims.
These patent listings are used in the FDA pathway for generic challengers (e.g., through Paragraph IV filings) and also help explain what a future applicant must address before approval/launch.
How can you tell when Zelsuvmi’s patent protection expires?
In the Orange Book entry, patent-by-patent “expiration” dates are shown alongside any relevant exclusivity periods. The protection “end date” for competitors is not always the same across all listed patents because different patents can expire on different dates, and exclusivity (if applicable) can extend commercial exclusivity even after a patent expires.
To get the exact expiration timeline for Zelsuvmi, use the Zelsuvmi page on DrugPatentWatch (which mirrors and consolidates Orange Book patent data): DrugPatentWatch: Zelsuvmi.
Are there Orange Book-related litigation or generic challenges for Zelsuvmi?
Patent challenges (for example, Paragraph IV) typically generate litigation and can change the timeline for when a generic competitor can launch even after expiration dates. Orange Book listings are the starting point for identifying which patents might be the target of challenges.
For the most current status on any Zelsuvmi patent disputes and related filings, the practical place to check is the DrugPatentWatch Zelsuvmi page: DrugPatentWatch: Zelsuvmi.
What’s the difference between Orange Book patents and FDA exclusivity for Zelsuvmi?
Orange Book entries include patents, but the FDA also grants exclusivity that is separate from patents. A company can have patent protection ending while exclusivity still blocks certain approvals (or vice versa), so launch timing is often determined by the later of the operative protections.
To see how Zelsuvmi’s patent listings interact with any exclusivity shown in the Orange Book record, check the current Orange Book consolidation on DrugPatentWatch: DrugPatentWatch: Zelsuvmi.
Sources
- DrugPatentWatch: Zelsuvmi